GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Marrone Bio Innovations Inc (NAS:MBII) » Definitions » Long-Term Debt & Capital Lease Obligation

Marrone Bio Innovations (Marrone Bio Innovations) Long-Term Debt & Capital Lease Obligation : $9.75 Mil (As of Mar. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Marrone Bio Innovations Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Marrone Bio Innovations's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $9.75 Mil.

Warning Sign:

Marrone Bio Innovations Inc keeps issuing new debt. Over the past 3 years, it issued USD 5.624 million of debt.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Marrone Bio Innovations's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $9.75 Mil. Marrone Bio Innovations's Total Assets for the quarter that ended in Mar. 2022 was $76.21 Mil. Marrone Bio Innovations's LT-Debt-to-Total-Asset for the quarter that ended in Mar. 2022 was 0.13.

Marrone Bio Innovations's LT-Debt-to-Total-Asset declined from Mar. 2021 (0.25) to Mar. 2022 (0.13). It may suggest that Marrone Bio Innovations is progressively becoming less dependent on debt to grow their business.


Marrone Bio Innovations Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Marrone Bio Innovations's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marrone Bio Innovations Long-Term Debt & Capital Lease Obligation Chart

Marrone Bio Innovations Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.23 19.12 23.12 21.83 10.20

Marrone Bio Innovations Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.60 21.28 20.91 10.20 9.75

Marrone Bio Innovations Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Marrone Bio Innovations  (NAS:MBII) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Marrone Bio Innovations's LT-Debt-to-Total-Asset ratio for the quarter that ended in Mar. 2022 is calculated as:

LT-Debt-to-Total-Asset (Q: Mar. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2022 )/Total Assets (Q: Mar. 2022 )
=9.745/76.214
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Marrone Bio Innovations Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Marrone Bio Innovations's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Marrone Bio Innovations (Marrone Bio Innovations) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7780-420 Brier Creek Parkway,, Raleigh, NC, USA, 27617
Marrone Bio Innovations Inc is a US-based agricultural company engaged in the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. The company produces bio-based pest management and plant health products such as Biopesticides, Bioinsecticides, Bionematicides, Biofungicides, Biostimulants and Bionutrition, among others. It generates key revenue from the sales of Marrone products, mainly Regalia, Grandevo and Venerate.
Executives
Pamela G Marrone director, officer: CEO and President C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Ladon Johnson officer: Interim CFO C/O MARRONE BIO INNOVATIONS, INC. 7780-420 BRIER CREEK PARWAY RALEIGH NC 27617-7882
Ardsley Ridgecrest Partners Fund, L.p. other: See Footnote (1) 262 HARBOR DRIVE, 4TH FLOOR, STAMFORD CT 06902
Suping (sue) Cheung officer: Chief Financial Officer C/O QUICKLOGIC CORPORATION, SUNNYVALE CA 94089
Matti Tiainen officer: SVP, International Sales C/O MARRONE BIO INNOVATIONS, INC. 1540 DREW AVENUE DAVIS CA 95618
Lara L Lee director C/O MARRONE BIO INNOVATIONS, INC., 1540 DREW AVENUE, DAVIS CA 95618
Kevin Helash director, officer: Chief Executive Officer C/O MARRONE BIO INNOVATIONS, INC. 1540 DREW AVENUE DAVIS CA 95618
Ardsley Advisory Partners Gp Llc other: See Footnotes(1)(2) 262 HARBOR DRIVE, 4TH FLOOR, STAMFORD CT 06902
Ospraie Management, Llc director, 10 percent owner, other: (See Remarks) 437 MADISON AVENUE, 28TH FLOOR, NEW YORK NY 10022
Ospraie Management, Inc. director, 10 percent owner, other: (See Remarks) 320 PARK AVENUE, 27TH FLOOR, NEW YORK NY 10022
Ospraie Holding I, L.p. director, 10 percent owner, other: (See Remarks) 320 PARK AVENUE, 27TH FLOOR, NEW YORK NY 10022
Dwight Anderson director, 10 percent owner, other: (See Remarks) C/O OSPRAIE MANAGEMENT, LLC, 320 PARK AVENUE, 27TH FLOOR, NEW YORK NY 10022
Ardsley Healthcare Fund, L.p. other: See Footnote (1) C/O ARDSLEY PARTNERS I GP, LLC, 262 HARBOR DRIVE, STAMFORD CT 06902
Ospraie Ag Science Llc director, 10 percent owner, other: (See Remarks) C/O DWIGHT ANDERSON 437 MADISON AVENUE, 28TH FLOOR NEW YORK NY 10022
Van Herk Investments B.v. 10 percent owner LICHTENAUERLAAN 30 ROTTERDAM P7 3062ME

Marrone Bio Innovations (Marrone Bio Innovations) Headlines

From GuruFocus

Marrone Bio Announces CFO Transition

By GuruFocusNews GuruFocusNews 02-22-2022